Biomarker-driven Trials
Biomarker-driven Trials - Related Videos
08:29
Biomarkers in an Animal Model for Revealing Neural, Hematologic, and Behavioral Correlates of PTSD
0 Views •
Cited by 29 •
2012
We describe a rat model of post traumatic stress disorder (PTSD) that reveals the persistent alterations in neuroendocrine function and the delayed long-term, exaggerated fear response, characteristic of PTSD patients. The animal model and methods described here are useful for correlating biomarkers in brain nuclei, which are mechanistic but cannot be measured in patients, with biomarkers in peripheral white blood cells, which can.
08:28
An Overview of bGDGT Biomarker Analysis for Paleoclimatology
0 Views •
2023
Source: Laboratory of Jeff Salacup - University of Massachusetts Amherst Throughout this series of videos, natural samples were extracted and purified in search of organic compounds, called biomarkers, that can relate information on climates and environments of the past. One of the samples analyzed was sediment. Sediments accumulate over geologic time in basins, depressions in the Earth into which sediment flows through the action of fluid (water or air), movement, and gravity. Two main types...
05:19
Closed-Loop Neurostimulation for Biomarker-Driven, Personalized Treatment of Major Depressive Disorder
0 Views •
Cited by 11 •
2023
Deep brain stimulation triggered by a patient-specific neural biomarker of a high-symptom state may better control symptoms of major depressive disorder compared to continuous, open-loop stimulation. This protocol provides a workflow for identifying a patient-specific neural biomarker and controlling the delivery of therapeutic stimulation based on the identified biomarker.
09:58
Light-driven Enzymatic Decarboxylation
0 Views •
Cited by 6 •
2016
We describe a protocol for the light-catalyzed generation of hydrogen peroxide — a cofactor for oxidative transformations.
01:28
The Trial Balance
0 Views •
2025
A trial balance is a fundamental financial statement that provides a snapshot of a company's accounts and their balances at a specific point in time. It serves as an essential tool for verifying the accuracy of financial records by ensuring that the total debits equal the total credits. Typically prepared at the end of an accounting period, a trial balance lists all ledger accounts in the order they appear, with debit balances in the left column and credit balances in the right column. The two...
FAQs
Biomarker-driven trials connect a biological measurement to a trial decision. A genetic variant, protein level, or imaging signal may determine who enters a study, which treatment they receive, or how response and safety are assessed. This linkage lets investigators test whether outcomes differ across biologically defined groups rather than treating the study population as uniform.
They convert biomarker measurements into consistent eligibility or assignment rules. A threshold can separate participants according to the level of a marker, while a molecular profile can combine biologic features to define a subgroup. Applying these criteria supports clearer comparisons between the intervention and the relevant patient group, making observed differences easier to relate to underlying biology.
By organizing participants according to measurable biology, the design can show that an intervention benefits some profiles but not others. A lack of benefit in a defined subgroup may indicate resistance associated with that biology, while stronger outcomes in another subgroup can identify patients more likely to respond. This connects treatment effects with disease characteristics.
A predictive marker is evaluated for its relationship to benefit from a particular intervention, whereas a prognostic marker is linked to expected clinical outcomes more generally. A pharmacodynamic marker is used to assess how the intervention affects biology during the study. Distinguishing these roles helps researchers determine whether a biomarker guides treatment choice, describes outcome, or measures biological response.
A typical workflow begins by collecting biomarker data, such as genetic, protein, or imaging measurements, and applying predefined thresholds or molecular profiles. Investigators then use the results for participant selection or treatment assignment and compare clinical response and safety within biologically defined groups. The final interpretation asks whether the marker relates to benefit, resistance, or treatment effects.
They are particularly relevant when an intervention is intended for a biologically selected population, including studies of targeted therapies. Enriching enrollment for patients more likely to respond can make treatment effects easier to evaluate, while comparing biological groups can expose resistance. The resulting evidence supports precision care and helps determine which markers deserve evaluation in future clinical research.